P-0178 - Prognostic relevance of KRAS mutation in colorectal cancer patients without microsatellite instability

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Biomarkers
Colon Cancer
Rectal Cancer
Presenter Fatemeh Khorshidi
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors F. Khorshidi1, M. Yaghoob Taleghani2, A. Irani Shemirani3, A. Pourhosseingholi Mohammad4, E. Nazemalhosseini Mojarad2, H. Asadzadeh Aghdaei5, R. Zali Mohammad2
  • 1Gastroenterology and Liver Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran/IR
  • 2Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran/IR
  • 3Department of Biomedical Engineering, Laboratory for Molecular and Cellular Dynamics, Boston/US
  • 4Basic and Molecular Epidemiology of Gastroenterology Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran/IR
  • 5Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran/IR

Abstract

Introduction

Background: Mutation of the KRAS (v-Kiras2 Kirsten rat sarcoma viral oncogene homologue) gene plays an important role in colorectal tumorigenesis. This study examined associations between KRAS gene mutations and clinicopathological and survival data in Iranian patients with microsatellite stable colorectal cancer (CRC).

Methods

CRC patients were recruited for the detection of KRAS gene mutations using polymerase chain reaction and DNA sequencing. Data on clinicopathological features and survival times were collected.

Results

The study included 123 MSS CRC patients. The overall mutation frequency of the KRAS gene was 15.44% (19/123). KRAS gene mutations were significantly associated with tumour location and liver metastasis. Univariate analysis showed that stage III were associated with poor prognosis in CRC patients (P = 0.030), whereas multivariate analysis showed that KRAS gene mutation and stage III were independent factors for survival (P = 0.022, P = 0.012 respectively).

Conclusion

These findings suggest that a low frequency of KRAS gene mutations exists in Iranian patients with MSS CRC, and that such mutations are associated with poor survival, tumour location and liver metastasis in MSS CRC patients.